Met in Urological Cancers
Met is a tyrosine kinase receptor that is considered to be a proto-oncogene. The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor growth, invasion, and metastasis in many types of malignancies. Furthermore, Met expression has been reported to be a useful predicti...
Main Authors: | Yasuyoshi Miyata, Akihiro Asai, Kensuke Mitsunari, Tomohiro Matsuo, Kojiro Ohba, Yasushi Mochizuki, Hideki Sakai |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/6/4/2387 |
Similar Items
-
Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies
by: Lucas Nogueira, et al.
Published: (2020-11-01) -
A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis
by: Yasuyoshi Miyata, et al.
Published: (2017-10-01) -
A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants
by: Yasuyoshi Miyata, et al.
Published: (2019-05-01) -
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers
by: Shoichiro Mukai, et al.
Published: (2020-04-01) -
Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy
by: Pranav Sharma, et al.
Published: (2016-01-01)